Reproductive Milestones as Predictors of Cardiometabolic Health: An Integrated Lifespan Perspective
DOI:
https://doi.org/10.64784/142Keywords:
Gynecologic health, Lifespan medicine, Polycystic ovary syndrome, Menopause, Cardiometabolic risk, Endocrine transition, Inflammation, Metabolic syndrome, Pregnancy-related hypertension, Women’s cardiovascular healthAbstract
Gynecologic health represents a dynamic interaction between endocrine regulation, metabolic homeostasis, inflammatory signaling, and cardiovascular adaptation across the female lifespan. Increasing evidence demonstrates that reproductive conditions such as polycystic ovary syndrome, endometriosis, uterine fibroids, hypertensive disorders of pregnancy, and menopause are not isolated clinical entities but manifestations of broader systemic processes. This review integrates high-impact clinical guidelines, consensus statements, and epidemiologic syntheses to construct a lifespan-based conceptual framework linking gynecologic milestones with long-term cardiometabolic risk. Polycystic ovary syndrome exemplifies the convergence of hyperandrogenism and insulin resistance with persistent vascular vulnerability. Endometriosis illustrates immune–endocrine interactions and chronic inflammatory pathways with potential systemic implications. Pregnancy-related hypertensive disorders function as prognostic markers of future cardiovascular disease, while the menopausal transition represents an endocrine inflection point that amplifies preexisting metabolic trajectories. The synthesis highlights inflammation as a unifying biological mediator and underscores the influence of global obesity and metabolic syndrome on reproductive outcomes. By reframing gynecology within systems medicine, this work emphasizes preventive reasoning, longitudinal risk stratification, and interdisciplinary care. A lifespan-integrated approach may strengthen medical education, improve early detection of cardiometabolic vulnerability, and redefine gynecologic practice as a cornerstone of long-term systemic health.
References
[1] R. S. Legro et al., “Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline,” J. Clin. Endocrinol. Metab., vol. 98, no. 12, pp. 4565–4592, 2013, doi: 10.1210/jc.2013-2350.
[2] A. E. Joham et al., “Polycystic ovary syndrome and cardiometabolic risk,” Lancet Diabetes Endocrinol., vol. 10, no. 9, pp. 668–680, 2022, doi: 10.1016/S2213-8587(22)00156-0.
[3] M. E. Pavone and H. M. Bulun, “Endometriosis and metabolic dysfunction,” N. Engl. J. Med., vol. 386, no. 2, pp. 150–160, 2022, doi: 10.1056/NEJMra2107068.
[4] J. A. Simon et al., “Menopause and cardiovascular disease risk,” Circulation, vol. 135, no. 7, pp. 595–608, 2017, doi: 10.1161/CIRCULATIONAHA.116.023063.
[5] NAMS (North American Menopause Society), “The 2022 hormone therapy position statement,” Menopause, vol. 29, no. 7, pp. 767–794, 2022, doi: 10.1097/GME.0000000000002028.
[6] S. R. Davis et al., “Global consensus position statement on the use of testosterone therapy for women,” Lancet Diabetes Endocrinol., vol. 7, no. 10, pp. 754–766, 2019, doi: 10.1016/S2213-8587(19)30189-5.
[7] E. R. Faubion et al., “Long-term health consequences of premature or early menopause,” JAMA, vol. 322, no. 4, pp. 372–380, 2019, doi: 10.1001/jama.2019.7617.
[8] L. M. Lobo et al., “Metabolic syndrome in women: Implications for reproductive health,” J. Clin. Endocrinol. Metab., vol. 106, no. 9, pp. e3512–e3525, 2021, doi: 10.1210/clinem/dgab344.
[9] WHO, “Global prevalence of obesity and its impact on women’s reproductive health,” Lancet, vol. 393, no. 10173, pp. 791–846, 2019, doi: 10.1016/S0140-6736(18)32482-2.
[10] M. R. Laughlin-Tommaso et al., “Uterine fibroids and systemic metabolic risk,” Obstet. Gynecol., vol. 135, no. 3, pp. 619–628, 2020, doi: 10.1097/AOG.0000000000003708.
[11] R. S. Taylor et al., “Inflammation and reproductive endocrinology,” Endocr. Rev., vol. 40, no. 4, pp. 1081–1114, 2019, doi: 10.1210/er.2018-00208.
[12] J. F. Strauss and R. L. Barbieri, Yen & Jaffe’s Reproductive Endocrinology, 8th ed., Elsevier, 2019, doi: 10.1016/C2016-0-03747-5.
[13] S. M. Ruan et al., “Cardiovascular risk factors in women across the lifespan,” Eur. Heart J., vol. 41, no. 24, pp. 2203–2212, 2020, doi: 10.1093/eurheartj/ehaa343.
[14] P. Santoro et al., “Hormonal changes during perimenopause and systemic implications,” J. Clin. Endocrinol. Metab., vol. 100, no. 9, pp. 3426–3433, 2015, doi: 10.1210/jc.2015-1629.
[15] A. H. DeCherney et al., Current Diagnosis & Treatment: Obstetrics & Gynecology, 12th ed., McGraw-Hill, 2019. doi: 10.1036/0071849080.
[16] S. E. Santen et al., “Managing menopausal symptoms with hormone therapy,” N. Engl. J. Med., vol. 376, no. 6, pp. 566–577, 2017, doi: 10.1056/NEJMra1504516.
[17] C. S. Welt and R. L. Carmina, “Lifelong health consequences of PCOS,” Lancet, vol. 393, no. 10180, pp. 1473–1486, 2019, doi: 10.1016/S0140-6736(18)31770-3.
[18] M. E. Hall et al., “Hypertension and pregnancy-related cardiovascular risk,” Hypertension, vol. 76, no. 6, pp. 1654–1662, 2020, doi: 10.1161/HYPERTENSIONAHA.120.15199.
